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Autophagy comprises the processes of autophagosome syn-
thesis and lysosomal degradation. In certain stress conditions,
increased autophagosome synthesis may be associated with
decreased lysosomal activity, which may result in reduced pro-
cessing of the excessive autophagosomes by the rate-limiting
lysosomal activity. Thus, the excessive autophagosomes in such
situationsmay be largely unfused to lysosomes, and their forma-
tion/accumulation under these conditions is assumed to be
futile for autophagy. The role of cytotoxicity in accumulating
autophagosomes (representing synthesis of autophagosomes
subsequently unfused to lysosomes) has not been investigated
previously. Here, we found that accumulation of autophago-
somes compromised cell viability, and this effect was alleviated
by depletion of autophagosome machinery proteins. We tested
whether reduction in autophagosome synthesis could affect cell
viability in cell models expressing mutant huntingtin and -
synuclein, given that both of these proteins cause increased
autophagosome biogenesis and compromised lysosomal activ-
ity. Importantly, partial depletion of autophagosomemachinery
proteins Atg16L1 and Beclin 1 significantly ameliorated cell
death in these conditions. Our data suggest that production/
accumulation of autophagosomes subsequently unfused to lyso-
somes (or accumulation of autophagosomes) directly induces
cellular toxicity, and this process may be implicated in the
pathogenesis of neurodegenerative diseases. Therefore, lower-
ing the accumulation of autophagosomes may represent a ther-
apeutic strategy for tackling such diseases.
Macroautophagy (referred to as “autophagy” hereafter) is an
intracellular degradation process thatmediates the bulk clearance
of long-lived and aberrant proteins, defective organelles, and cer-
tain pathogens. Autophagy provides a source of nutrition during
periods of stress to promote healthy cell homeostasis and boost
survival. Autophagy proceeds through the sequential nucleation
and elongation of a double-membraned vesicle called an autopha-
gosome, encapsulating a portion of the cytoplasm in the process.
Autophagosomes then shuttle to lysosomes, whereupon the vesi-
cles fuse, forming an autolysosome. The acidic pH and enzymatic
action of hydrolases within the lysosome lead to the breakdown
of the internal membranes of autophagosomes as well as the
autophagosomes’ contents (1). This clearancehas been implicated
in a diverse range of pathologies, including tumorigenesis, neuro-
degenerative disease, and infection, among others (2).
The various stages of autophagy each have their own set of
regulators. The most well-characterized master controller of
the process is the target of rapamycin complex (TOR,2 mTOR
in mammals), which serves to repress autophagosome biogen-
esis and autophagy under basal and stimulation conditions.
Upon the onset of certain stresses, when TOR is deactivated,
autophagosome biogenesis and autophagy are initiated (3).
Autophagosome formation is mediated by a dedicatedmachin-
ery of autophagy-related (Atg) genes. Originally observed in
yeast, the Atg family is highly conserved across species, and
nearly 40 members have been identified. The sequential ULK1
and Beclin 1–Vps34 complexes are required to nucleate the
developing autophagosome membrane (4, 5). Two ubiquitin-
like conjugation reactions then elongate the membrane to the
completed double-membraned autophagosome. In these reac-
tions, different Atg proteins serve roles akin to the E1- and
E2-like enzymes found in the ubiquitin-proteasome system. The
first involves the conjugation of Atg12 to Atg5, facilitated by Atg7
(E1-like) and Atg10 (E2-like) (6). This Atg12–5 then binds non-
covalently to Atg16 (7). In the second, LC3 is cleaved by Atg4 and
conjugated to phosphatidylethanolamine via Atg7 (E1) and Atg3
(E2) (6, 8, 9), and the Atg5–12–Atg16 complex serves as an E3
ligase to stimulate LC3-phosphatidylethanolamine or LC3-II con-
jugation (10–12). LC3-II remains associatedwith autophagosome
membranes following completion,making it awidely usedmarker
for these vesicles (13). Interestingly, recent data suggest that
although the ATG (autophagy-related gene) conjugation systems
are critical for autophagosome completion, theymay not be abso-
lutely essential for the process (14, 15).
Once completed, autophagosomes and their cargo are shut-
tled to lysosomes for fusion and subsequent degradation. Mul-
tiple complexes appear to facilitate autophagosome–lysosome
fusion. These include the lysosome-associated membrane pro-
teins 1 and 2 (LAMP-1 and LAMP-2), the two proteins required
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for the trafficking of lysosomes and autophagosome–lysosome
fusion (16, 17). The SNARE syntaxin-17 (STX-17) is recruited
to completed autophagosomes and interacts with SNAP29 and
the lysosomal SNARE VAMP-7, serving as a tether between
autophagosomes and lysosomes (18). Components of the
HOPS complex, such as VPS16, VPS33A, and VPS39, have
also been shown to interact with STX-17 and aid this process
(19, 20). As such, genetic ablation of any of these proteins
results in a blockade to autophagy flux, causing accumula-
tions of non-fused autophagosomes. Lysosomal degradation
is dependent on an acidic pH (21), meaning that chemical
agents like bafilomycin-A1 (Baf) and chloroquine (CQ),
which reduce acidity, also cause a disruption to autophagy
flux (22, 23).
Currently, autophagy is largely believed to function as a pro-
survival process due to its critical role in cellular energy and
nutrition homeostasis, and autophagy inhibition compromises
cell viability (24). Various stress conditions, such as oxidation
and toxic protein aggregation, often concurrently induce both
compromised autolysosomal activity and increased autophago-
some synthesis (25). In these conditions, the excessive autopha-
gosomes resulting from the elevated synthesis cannot be pro-
cessed by the rate-limiting compromised lysosomal activity.
Thus, the excessive autophagosomes are non-fused, and their
synthesis/accumulation in the conditions may be a futile pro-
cess for autophagy. Although defective autolysosomal activity
is well recognized to exacerbate cell survival (26), it has not
been investigated whether accumulation of autophagosomes,
which represents the synthesis of autophagosomes that subse-
quently fail to fuse with lysosomes, also contributes to the cell
toxicity in stress conditions. In this study, we exploited genetic
and chemical inhibition approaches to dissect the effects of
increased autophagosome formation or lysosomal dysfunction
on cell viability, both alone and in combination with one
another (the latter strategy representing accumulation of
autophagosomes). We found that defects in autophagosome–
lysosome fusion or lysosomes alone do not induce sufficient
cellular toxicity. However, increased autophagosome synthesis
cooperates with defective lysosomal activity to synergistically
induce cell toxicity/death. These data, for the first time,
highlight that accumulation of autophagosomes directly
exerts cellular toxicity during late-stage autophagy inhibi-
tion. Our data also suggest that autophagosome synthesis
appears to be required for the toxicity caused by defects in
autophagosome–lysosome fusion or lysosomes. Impor-
tantly, we confirm that partial depletion of autophagosome
machinery proteins indeed alleviates cell death in cells
expressing toxic mutant huntingtin and -synuclein. There-
fore, our findings may be implicated in the pathogenesis and
therapies of neurodegenerative diseases.
Results
Simultaneous ablation ofmTOR and STX-17 synergistically
causes production/accumulation of non-fused
autophagosomes
Previously, we reported (27) that PI3K/mTOR dual kinase
inhibitors induce cell death aswell as stimulate autophagosome
biogenesis while also causing a defect in autophagosome–
lysosome fusion. We reasoned that although autophagy is usu-
ally a pro-survival process, increased autophagosome biogene-
sis may be a contributing factor to toxicity in such contexts.
Because in these circumstances there is disruption to auto-
phagosome–lysosome fusion, the autophagosomes cannot be
processed. This therefore means that they can be considered as
non-fused autophagosomes, which yield no survival benefits
and may instead pose cell toxicity. We began by testing this
hypothesis via the use of the autophagy inducer rapamycin
(Rap) and the lysosomal de-acidifier CQ.Whereas single use of
Rap caused no significant alteration to cell viability, CQ did
produce a notable decline. Importantly, this viability loss could
be exacerbated further by combining the two drugs, suggesting
that increased autophagosome biogenesis in periods of lyso-
somal failure (accumulation of autophagosomes)may exert cell
toxicity (supplemental Fig. S1).
To further test whether the accumulation of autophago-
somes exerts cytotoxicity, we next aimed to establish a model
that represents the conditions for the formation of non-fused
autophagosomes by using siRNA as a more specific genetic
approach. We thus targeted the negative regulator of auto-
phagy-mTOR (3) and one of the key autophagosome–lysosome
fusion mediators, STX-17 (18), using siRNA, to induce
autophagosome synthesis and disrupt degradation, respec-
tively. To ensure that this strategy exerts the desired effect on
autophagosomes, we first utilized cells stably expressingmRFP-
GFP-LC3. This system enables the distinction between non-
fused autophagosomes and autolysosomes, because the acidic
lysosomal pH quenches GFP (28). Consistent with our expec-
tations, siRNAknockdown of STX-17 led to an increase in non-
fused autophagosomes, which was exacerbated further when
coupled with mTOR knockdown (Fig. 1, A–C). To fortify these
LC3 counts, we also assessed numbers of autophagic vesicles by
EM. These results concurred with the mRFP-GFP-LC3 data,
with synergistic knockdown of mTOR and STX-17 yielding a
greater number of autophagosomes than either siRNA alone
(Fig. 1, D and E). In addition, immunoblot analysis of LC3-II
levels showed similar effects. Notably, co-treatment with the
lysosomal inhibitor CQ only efficiently elevated LC3-II in the
control or mTOR single knockdowns, consistent with the role
of STX-17 in mediating autophagosome–lysosome fusion (Fig.
1, F and G). Together, these results highlight the dual knock-
downofmTORand STX-17 as a validmethod to generate accu-
mulation of autophagosomes.
Simultaneous ablation ofmTOR and STX-17 synergistically
causes cell viability loss
Interestingly, combination of mTOR and STX-17 siRNA led
to a synergistic decline in cell viability, greater than the viability
loss caused by treatment with mTOR siRNA or STX-17 siRNA
alone (Fig. 2,A and B). With the combination treatments prov-
ing the most detrimental to the cells, these data suggest that
increased autophagosome synthesis, in addition to lysosomal
defect, is required for sufficient cytotoxicity. Notably, whereas
depletion of STX-17 alone did not cause any significant
changes, single mTOR knockdown did cause a decrease in via-
bility. This is not surprising, because mTOR is a master regula-
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tor of growth andproliferation, two factors that are also encom-
passed by viability measures in addition to cell health and
survival. To account for this, we measured proliferation under
the same conditions and corrected the viability against the pro-
liferation (supplemental Fig. S2). Importantly, whereas the via-
bility decrease was mostly lost in mTOR single siRNA treat-
ment after proliferation factor was excluded, a significant
decline was still evident for the combination treatment by
mTOR siRNA and STX-17 siRNA after the exclusion of prolif-
eration factor, indicating a significant degree of cell toxicity
and/or death in the dual knockdown conditions (supplemental
Fig. S2). We also confirmed that levels of cell death detectable
by propidium iodide staining in flow cytometry were increased
in the conditions (Fig. 2,C andD). Of note, the cell death rate is
lower than that of viability loss, given that it only accounts for a
portion of the toxicity. To ensure that the effects on viability
loss from STX-17 siRNA knockdown were via its inhibition of
autophagosome–lysosome fusion, and not some as yet unre-
ported off-target roles, we also used mTOR shRNA and
STX-17 shRNA for the experiments. Fig. 2E shows that
Figure 1. Establishment of a model for production/accumulation of non-fused autophagosomes by simultaneous ablation of mTOR and STX-17. A,
immunoblotwas used to confirm the knockdownefficiency ofmTOR and STX-17 siRNA transfection inHeLa cells over 72 h. B, mRFP-GFP-LC3 stably expressing
HeLa cellswere transfectedwith control,mTOR, STX-17, ormTOR STX-17 siRNA for 72 h. The number of autophagosomes (green vesicles) and autolysosomes
(red vesiclesminus green vesicles) was assessed (n 20 cells/condition). Data are shown asmean S.D. (error bars). *, p 0.05; ***, p 0.001. C, representative
confocal images for the cells inBwere collected. Scale bar, 20m.D, HeLa cellswere transfectedwith siRNAs as indicated for 48h. Imageswere acquiredbyTEM
microscopy. Black arrows, indicate autophagosomes; arrowheads, autolysosomes; asterisks, mitochondria. E, quantification of autophagosomes in 25–26 cells
for each condition. dKD, dual knockdown (mTOR/STX-17 siRNA). *, p 0.05; ***, p 0.001. F, HeLa cells were transfected as in B, with vehicle or CQ (25 M)
treatment for the last 24 h. Cell lysateswere subjected to immunoblotting andprobedwith the indicated antibodies.G, LC3-II levels in Fwere quantified versus
loading control (actin). Data are shown as mean -fold change S.D. (n 3). *, p 0.05; ***, p 0.001; NS, not significant.
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mTOR/STX-17 shRNA dual knockdown consistently in-
duced cytotoxicity. These data suggest that autophagosome
biogenesis stimulated by mTOR knockdown is important to
sensitize cells to lysosomal defects or that formation/accu-
mulation of non-fused autophagosomes can directly exert
cytotoxicity.
We fortified these experiments with some additional drug
strategies. We have previously shown the dual PI3K/mTOR
inhibitor PI-103 to stimulate autophagosome formation while
blocking degradation to a degree (27), which can be exacer-
bated further by coupling it with lysosomal the de-acidifier CQ
or Baf. With these drug treatments, we again observed that
whereas single administration of either agent caused a signifi-
cant decline in viability, the effect could be exacerbated dramat-
ically by using the two in combination (supplemental Fig. S3, A
and B). Also, total loss of viability was achievable at much lower
concentrations of PI-103 when used with Baf (supplemental
Fig. S3C). As well as assessing changes to cell viability, we also
measured the cytotoxicity under conditions of autophagosome
synthesis with lysosomal blockade. Consistent with our previ-
ous measurements, we found that the toxicity associated with
lysosomal inhibition could be exacerbated by coupling it with
an autophagosome synthesis inducer (Rap) (supplemental Fig.
S3D). Together, these results further support a toxic role for
accumulation of autophagosomes achieved through a com-
bination of elevated autophagosome synthesis coupled with
decreased degradation.
Increased accumulation of autophagosomes through diverse
targets widely induces cytotoxicity
To ensure that the effects on viability loss from mTOR/
STX-17 dual knockdown were attributable to the increased
formation of autophagosomes coupled with inhibition of
autophagosome–lysosome fusion, we aimed to replicate the
toxicity with alternative targets. Vps33A is a member of the
HOPS complex and also has been shown to be necessary for
autophagosome–lysosome fusion (19).We confirmed this with
cells stably expressing mRFP-GFP-LC3. As with STX-17
knockdown, ablation of Vps33A caused a blockade to autolyso-
some formation, with an increase in the number of non-fused
autophagosomes (Fig. 3, A and B). Importantly, this could be
exacerbated by pairing Vps33A siRNAwithmTOR siRNA (Fig.
3, A and B). This combination effect was also translated to cell
viability. Simultaneous Vps33A andmTORknockdown consis-
tently led to a significant decline in cell viability, to a degree
comparable with that with mTOR and STX-17 siRNA combi-
nations (Fig. 3C). mTOR and Vps33A knockdown was con-
firmed by qPCR (Fig. 3,D and E). Other importantmediators of
autophagosome–lysosome fusion are the LAMP proteins (29,
30). Therefore, LAMP1/2 double knock-out cells represent an
alternative model for autophagosome clearance failure. Nota-
bly, we found the viability of LAMPdouble knock-out cells to be
more sensitive to exposure to starvation conditions, a bona fide
stimulator of autophagosome synthesis, than the wild type
(supplemental Fig. S4A). These data further indicate that pro-
duction of autophagosomes is toxic under periods of lysosomal
failure.
Figure 2. DualmTOR/STX-17 knockdown causes cell viability loss. A, HEK293 cells were transfected with control, mTOR, STX-17, or mTOR STX-17 siRNA
for 72 h, and cell viability was measured with an MTT assay (n 6 cells/condition). Data are shown as mean S.D. (error bars). *, p 0.05; ***, p 0.001. B,
matching phase-contrast images were acquired. Scale bar, 100 m. C, HEK293 cells were transfected as in A, and cell death was measured using propidium
iodide staining in flow cytometry (n 6/treatment). D, results from C are shown as mean S.D. **, p 0.01. E, HEK293 cells were transfected with control,
mTOR, STX-17, or mTOR  STX-17 shRNA for 72 h, and cell viability was measured (n  6 cells/condition). Data are shown as mean  S.D. ***, p  0.001.
Knockdown efficiency was confirmed by immunoblotting.
Figure 3. Increased synthesis/accumulation of non-fused autophago-
somes through diverse targets widely induces cytotoxicity. A, HeLa cells
stably expressing mRFP-GFP-LC3 were transfected with control, mTOR,
Vps33A, or mTOR  Vps33A siRNA for 72 h. Cells were fixed, and confocal
images were collected. Scale bar, 20 m. B, the number of autophagosomes
(green vesicles) and autolysosomes (red vesicles minus green vesicles) from A
was assessed (n 20 cells/condition). Data are shown as mean S.D. (error
bars). *, p 0.05; ***, p 0.001. C, HEK293 cells were transfected as in A, and
viability was measured with an MTT assay (n  6 cells/condition). Data are
shown asmean S.D. *, p 0.05; ***, p 0.001.D, knockdown efficiency for
the mTOR siRNA was confirmed with qPCR. E, knockdown efficiency for the
VPS33A siRNA was confirmed with qPCR. F, HEK293 cells were transfected
with control, IMPA, SNAP29 (SNAP), or IMPA SNAP siRNA for 72 h. Cell via-
bilitywasmeasuredwith anMTTassay (n5 cells/condition). Data are shown
as mean S.D. *, p 0.05; **, p 0.01; ***, p 0.001. Knockdown efficiency
was confirmed with immunoblotting.
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Given that mTOR also regulates other cellular pathways
in addition to autophagosome synthesis, we wanted to en-
sure that our toxicity measurements were not attributable to
additional roles of mTOR. Therefore, our attention turned
to utilizing mTOR-independent methods to stimulate
autophagosome synthesis. Several mTOR-independent
mechanisms of autophagy activation have been identified,
including via the inositol signaling pathway. Studies have
shown that reductions in free inositol lead to enhanced
autophagosome synthesis (31). For this reason, we opted to tar-
get inositolmonophosphatase 1 (IMPA)with siRNA as ameans
to induce autophagosome generation without disrupting
mTOR. Consistent with our expectations, we confirmed IMPA
knockdown to yield an increase in autophagosome numbers,
which could be elevated further when coupled with CQ (sup-
plemental Fig. S4, B and C). With IMPA appearing to be a suit-
able target for autophagosome synthesis, we explored whether
combining it with lysosomal inhibition could cause toxicity as
before. We paired IMPA with SNAP29, which has been dem-
onstrated to be important for autophagosome–lysosome fusion
(18), as shown in supplemental Fig. S4,B andC. Importantly, we
found that whereas knockdown of either IMPA or SNAP29
alone led to a modest reduction in cell viability, this could be
dramatically enhanced by combining the treatments (Fig. 3F).
Chemical strategies to induceautophagosomesynthesis inde-
pendent of mTOR have also been developed. We selected ril-
menidine (Ril), which stimulates autophagosome synthesis by
reducing cAMP levels (32), to fortify our IMPA observations.
Importantly, whereas Ril itself caused no viability decline, it did
synergize with CQ to cause significant cell viability loss (sup-
plemental Fig. S4D). Together, these data suggest that mTOR-
independent stimulation of autophagosome synthesis synergis-
tically induces cytotoxicity when coupled with lysosomal
defect,much likemTOR inhibition. These complementary data
strongly suggest that increased autophagosome synthesis in-
duces cytotoxicity in the case of autophagosomes not being
processed by lysosomes.
Autophagosome synthesis is required for the toxicity
associated with accumulation of autophagosomes
Our data suggest that dual mTOR/STX-17 knockdown
toxicity may be attributable to non-fused autophagosome
formation. Therefore, we next asked whether a reduction
in autophagosome biogenesis can alleviate mTOR/STX-17
dual knockdown toxicity. As such, we inhibited autophago-
some synthesis through the use of siRNAs targeting Atg16L1
(Fig. 4, A and B) or Atg10 (Fig. 4C), two key mediators of
autophagosome elongation. Intriguingly, we found that follow-
ing the depletion of autophagosome formation, the viability
loss induced bymTOR/STX-17 knockdownno longer occurred
(Fig. 4,A–C). Similar to this, depletion of Atg16L1 also caused a
reduction in toxicity associated with IMPA/SNAP29 knock-
down (supplemental Fig. S5A). These data suggest that contin-
ued autophagosome synthesis is required for the loss of cell
health under these conditions.
To complement these experiments, we also utilized auto-
phagy chemical inhibition strategies to see whether these could
alleviate the relevant viability losses. 3-Methyladenine (3MA) is
a pan-PI3K inhibitor and thus can inhibit autophagosome syn-
thesis due to the role of the class III PI3K in the process (33, 34).
Notably, we found the addition of 3MA to greatly reduce the
viability loss associated with PI-103 treatment (supplemental
Fig. S5B). We also utilized an autophagosome synthesis-null
cell line, Atg16L1 KO MEFs. In these cells, the depletion of
autophagosome synthesis led to a significant reduction in the
toxicity associated with both PI-103 and Baf, with the most
notable rescue arising from the combination treatments with
the two drugs (supplemental Fig. S5C).
From these findings, we conclude that when lysosomal func-
tion is blocked, autophagosome synthesis or accumulation of
autophagosomes, a futile action of autophagosome synthesis,
exerts cellular toxicity. The toxicity could be relevant in various
pathological conditions. For instance, dementia diseases with
Figure 4. Autophagosome synthesis is necessary for the viability loss by
dualmTOR/STX-17 knockdown. A, HEK293 cells were transfectedwith con-
trol ormTOR STX-17 siRNA in the absence or presence of Atg16L1 siRNA, as
indicated, for 72 h. Cell viability was measured with an MTT assay (n  6
cells/condition). Data are shown as mean  S.D. (error bars). ***, p  0.001.
Knockdown efficiency was confirmed by immunoblotting. B, matching
phase-contrast imageswere acquired. Scale bar, 100m.C, HEK293cellswere
transfectedwith control ormTOR STX-17 siRNA in the absence or presence
of Atg10 siRNA, as indicated, for 72 h. Cell viability was measured with MTT
assay (n 6 cells/condition). Data are shown as mean S.D. ***, p 0.001.
Knockdown efficiency was confirmed by immunoblotting.
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toxic protein aggregates can be associated with compromised
lysosomal activity (35), and the toxicity stress induced by this
could in turn also increase autophagosome synthesis, leading to
accumulation of autophagosomes.
Accumulation of autophagosomes causes cell viability loss
independent of apoptosis and necroptosis
We next aimed to uncover the potential mechanism
through which autophagosome accumulation toxicity oc-
curs. Apoptosis and necroptosis are the two main routes of
cell death, so we examined whether they are involved in
autophagosome accumulation toxicity. Apoptosis is inhib-
ited by the pan-caspase inhibitor benzyloxycarbonyl-VAD-
fluoromethyl ketone (Z-VAD-fmk) (36), and necroptosis can
be blocked by necrostatin-1 (Nec) (37), a selective inhibitor of
RIP1 that is essential for RIP1-RIP3-dependent necroptosis
(38–40). We tested whether the addition of these inhibitors
could rescue cell viability loss caused by mTOR/STX-17 dual
knockdown. We observed that mTOR/STX-17–induced cell
viability loss was largely unaffected by either Z-VAD-fmk or
Nec treatment (Fig. 5A), suggesting that this toxicity is indepen-
dent of apoptosis and necroptosis.We fortified this observation
by employing genetic strategies to ablate apoptosis or necrop-
tosis, with siRNAs against caspase-3 (an apoptosis executioner
Figure 5. Accumulation of autophagosomes causes cell viability loss independent of apoptosis and necroptosis. A, HEK293 cells were transfectedwith
control, mTOR, STX-17, or mTOR STX-17 siRNA for 48 h and then treated with pan-caspase inhibitor Z-VAD-fmk (zVAD) (20 M) or necroptosis inhibitor Nec
(20M), as indicated, for a further 24 h. Cell viability was thenmeasuredwithMTT assay (n 6 cells/condition). Data are shown asmean S.D. (error bars). ***,
p 0.001. B, HEK293 cells were transfected with control or mTOR STX-17 siRNA in the absence or presence of caspase-3 siRNA, as indicated, for 72 h. Cell
viability was measured with an MTT assay (n  6 cells/condition). Data are shown as mean  S.D. *, p  0.05. Knockdown efficiency was confirmed by
immunoblotting. C, HEK293 cells were transfected with control or mTOR STX-17 siRNA in the absence or presence of RIP1 siRNA, as indicated, for 96 h. Cell
viability was measured with MTT assay (n  6 cells/condition). Data are shown as mean  S.D. ***, p  0.001. Knockdown efficiency was confirmed by
immunoblotting.D, HeLa cells were transfectedwith control, mTOR, STX-17, ormTOR STX-17 (dKD) siRNA for 72 h andwith the apoptosis inducer STS (1M)
for 24 h as a positive control. Cell lysates were analyzed by immunoblot and probed with the indicated antibodies. E, HeLa cells were treated with siRNAs as
indicated for 48 h or STS (1 M) for 24 h. Images were acquired with TEM.
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(41)) to block apoptosis or against RIP1 for necroptosis inhibi-
tion. Consistently, disruption to either of the pathways did little
to alleviate the viability loss with mTOR/STX-17 knockdown
(Fig. 5, B and C). These results further confirm that apoptosis
and necroptosis are not major determinants for the toxicity
caused by accumulation of autophagosomes when auto-
phagosome–lysosome fusion is compromised.
We also examined whether the addition of these inhibitors
could rescue cell death associated with PI-103 and CQ treat-
ment. Indeed, the massive extent of cell death caused by the
combination of PI-103 and CQ was not reduced by either
Z-VAD-fmk or Nec, further suggesting this lethality to be
largely independent of apoptosis and necroptosis (supplemen-
tal Fig. S6, A and B). Additionally, we did not detect any
caspase-3 cleavage fragments (which are a hallmark of apopto-
sis (41)) in the cells with mTOR/STX-17 treatment (Fig. 5D).
TEM images show that the cells treated with either the single
siRNA knockdown or mTOR/STX-17 siRNA dual knockdown
do not show a damaged or fragmented nuclear morphology, as
seen in the cells treated with the apoptosis inducer staurospo-
rine (Fig. 5E).
Accumulation of autophagosomes causes an energy deficit
and elevates reactive oxygen species (ROS)
Because apoptosis and necroptosis did not seem to influence
the loss in viability caused by the accumulation of autophago-
somes, we turned to further elucidating themechanisms under-
lying this effect. Because autophagy is important in the removal
of various intracellular toxins, we reasoned that accumulation
of autophagosomes could result in the harmful persistence of
certain agents. One such example is ROS, with autophagy pro-
viding protection by their direct removal as well as eliminating
their source, defective mitochondria. Indeed, we observed a
significant increase in overall ROS levels in mTOR and STX-17
siRNA–transfected cells, both over control and single siRNA
treatment, suggesting that these may contribute to the toxicity
Figure 6. Accumulation of autophagosomes causes an increase in ROSwhile depleting ATP levels. A, HEK293 cells were transfectedwith control, mTOR,
STX-17, or mTOR STX-17 siRNA for 72 h, and ROS levels weremeasured in flow cytometry via dihydroethidium (DHE) staining (n 3 cells/condition). B, data
from A are shown as mean S.D. (error bars). Treatment with 1 mM H2O2 for 30 min was used as a positive control. **, p 0.01; ***, p 0.001. C, HEK293 cells
were treated with control, mTOR, STX-17, mTOR STX-17, VPS33A, or mTOR VPS33A siRNA as indicated for 72 h, and ATP levels were measured via an ATP
assay kit (Promega) (n 6 cells/condition). Data are shown asmean S.D. **, p 0.01; ***, p 0.001.D, HEK293 cells were treatedwith control, IMPA, SNAP29
(SNAP), or IMPA SNAP siRNA for 72 h, and ATP levels were measured as in C (n 6/condition). Data are shown as mean S.D. *, p 0.05; ***, p 0.001.
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(Fig. 6, A and B). Interestingly, a subpopulation of cells, partic-
ularly STX-17/mTOR knockdown cells, that undergoes pro-
nounced ROS production exhibits significant cell size increases
indicated by forward-scattered light (FSC) counts (Fig. 6A).
This suggests that the enlargement of cell size is associatedwith
ROS production. Currently, little is known about how cell size
homeostasis is regulated. However, evidence suggests that ROS
production concurs with cell size increase during cell senes-
cence (42), and H2O2 treatment leads to cell enlargement, at
least over an extended time frame (43). It would be interesting
to reveal whether ROS is an upstream stimulus to positively
regulate cell size in this case.
Another important lifeline that autophagy provides cells is
an energy supply via the degradation and recycling of unneces-
sary materials. We explored whether this source was disrupted
under our toxic knockdown treatments by assessing intracellu-
lar ATP levels. Despite a significant decrease in ATP levels with
mTOR knockdown treatment (presumably due to the roles of
mTOR in cell metabolism (44)) and a modest ATP reduction
with STX-17 or VPS33A knockdown, the combination of
mTOR and STX-17/VPS33A siRNA caused a marked and syn-
ergistic decline in the ATP levels (Fig. 6C). We found a similar
effect to occur by coupling IMPA1 with SNAP29, highlighting
this event as occurring independently of mTOR inhibition (Fig.
6D). Therefore, it seems that the energy deficit resulting from
defective autophagy degradation also contributes to autopha-
gosome accumulation toxicity. Under these conditions, the
newly formed autophagosomes cannot be fused and prove
futile. Autophagosome accumulation induction would only
exert a further demand on the cell’s energy stores through the
continued production of non-fused autophagosomes, which
ultimately proves toxic. Thus, the costs of autophagosome
accumulation may be culpable for, or at least contribute to, the
toxicity that we observe.
Lowering accumulation of autophagosomes by partial
depletion of autophagosome synthesis provides a rescue from
aggregation-prone protein toxicity
Many neurodegenerative diseases are associated with toxic
protein aggregates, which have been shown to disrupt auto-
phagy dynamics. Reports indicate that whereas the presence of
these aggregates induces autophagosome synthesis, they also
disrupt the degradation process (45–47). Therefore, ourmodel
of autophagosome accumulation–based toxicity seems rele-
vant in these pathologies. We found the SK-N-SH neuroblas-
toma cell line to be sensitive to autophagosome accumulation
inducing drug treatment (supplemental Fig. S1), so we opted to
use these cells for our further autophagosome accumulation
toxicity experiments. We aimed to assess whether autophago-
some accumulation contributes to the toxicity of mutant hun-
tingtin with expanded polyQ that causes Huntington’s disease,
in Huntington’s disease cell models. To confirm that these
cells are suitable for this study, we first assessed whether
autophagosome–lysosome fusion was disrupted in neuronal
SK-N-SH cells expressing mRFP-GFP-LC3, by comparing
mutant huntingtin with 72Q (mHTT) versus wild-type hun-
tingtin exon 1with 21Q (wtHTT).We foundmHTT to cause an
increase in the number of non-fused autophagosomes com-
pared with the wtHTT (Fig. 7, A and B), while not altering
lysosomal pH or morphology (supplemental Fig. S7A). Because
autophagosome numbers correlate with the levels of the
autophagosome-associated protein LC3-II (1), we also exam-
ined LC3-II levels by immunoblotting. Fig. 7 (C and D) shows
that LC3-II levels were markedly increased in mHTT-express-
ing cells when a lysosomal inhibitor was absent (Fig. 7C, lanes 1
and 2). After the treatment of the lysosomal inhibitor CQ for
both wtHTT- and mHTT-expressing cells, although the -fold
change in LC3-II levels was reduced, a significant increase was
still observed inmHTT-expressing cells (Fig. 7C, lanes 3 and 4).
The data (Fig. 7, C (lanes 3 and 4) and D) suggest that mHTT
increases autophagosome formation, and the reduced LC3-II
level change between wtHTT- and mHTT-expressing cells in
the presence of CQ (Fig. 7D) suggests that the lysosomal path-
way is defective in the cells expressing mHTT. We also con-
firmed that mHTT expression caused a significant increase in
cell death (supplemental Fig. S7B). These data suggest that
accumulation of autophagosomes occurs in cells expressing
mHTT. Therefore, we asked whether depletion of components
of the autophagosome formation machinery could alleviate the
cell death resulting from mHTT.
Because autophagy is usually a pro-survival process, in many
instances, strong ablation of the autophagy machinery can be
detrimental to cell survival. Indeed, we observed this in our
Atg10 and Atg16L1 knockdowns, which caused a degree of cell
viability loss (Fig. 4, A–C). Therefore, to boost the possible
translational relevance of our approach, we tested whether a
partial knockdown to autophagosome synthesis using a lower
siRNA dose (to ensure that cells retain sufficient autophagy
activity) could yield protective benefits for the cells undergoing
mHTT proteotoxicity. Following on from our earlier work (Fig.
4A), we started by targeting Atg16L1. Interestingly, we found
that partial knockdown of Atg16L1 afforded a significant
degree of protection from the cell death elicited from mHTT
(Fig. 7, E and F).
To fortify this observation, we selected an alternative medi-
ator of autophagosome formation, Beclin 1, the mammalian
Atg6 homologue (48). Beclin 1 functions in two complexes,
Complex I and Complex II, which influence autophagy at dif-
ferent stages. Complex I contains Vps34, Vps15, Beclin 1, and
Atg14 and is important for autophagosome formation (5).
However, Complex II, containing Beclin 1, UVRAG, and Rubi-
con, regulates the later process of autophagosome maturation
(49, 50). Therefore, there is the risk that Beclin 1 depletionmay
also perturb autophagy flux, which according to our model
would exacerbate the toxicity. To assess this, we investigated
autophagy dynamics during Beclin 1 knockdown in cells
expressing mRFP-GFP-LC3. Importantly, the numbers of
autophagosomes were largely decreased following Beclin 1
depletion, whereas autolysosomes were less affected (supple-
mental Fig. S7, C and D). These data suggest that autophago-
some formation is more severely affected by Beclin 1 depletion.
As such, we explored whether Beclin 1 partial depletion could
also provide a rescue from autophagosome accumulation tox-
icity in the cells with mHTT toxicity. Again, partial ablation of
Beclin 1 caused a decline in cell death, to an extent even greater
than that seenwithAtg16L1 (Fig. 6 (G andH) and supplemental
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Fig. S7E). Importantly, we found this effect to be true for two
different Beclin 1 siRNAs (Fig. 7I). Together, these results
suggest that partial reduction in autophagosome formation
alleviates autophagosome accumulation toxicity in mHTT-
expressing cells, thereby providing a rescue from mHTT
proteotoxicity.
Following our promising results with mHTT, we next tested
whether this was the case for another toxic neurodegenerative
protein, mutant -synuclein. Accumulations of this protein are
associated with Parkinson’s disease, with several reports dem-
onstrating it to disrupt autophagy flux (45–47). We confirmed
this to be true in our experimental conditions by assessing
autophagosome versus autolysosome numbers with mRFP-
GFP-LC3–expressing cells (Fig. 8, A and B), again seeing an
increase in non-fused or degraded vesicles, while not disrupting
lysosomal pH (supplemental Fig. S8). Similarly, we also exam-
ined LC3-II levels by immunoblot under these conditions. Fig. 8
(C and D) shows that LC3-II levels were largely increased in
-synuclein–overexpressing cells without CQ treatment (Fig.
8C, lanes 1 and 2). With CQ treatment, a significant increase
was still observed in -synuclein–overexpressing cells (Fig. 8C,
lanes 3 and 4). The data (Fig. 8C, lanes 3 and 4) suggest that
-synuclein overexpression increases autophagosome forma-
tion, and the reduced LC3-II increase in -synuclein-overex-
pressing cells in the presence of CQ (Fig. 8D) confirms that the
lysosomal pathway is defective in the cells overexpressing -sy-
nuclein. These findings indicate that autophagosome accumu-
lation also occurs in cells with -synuclein aggregates.
With Beclin 1 partial depletion proving to be markedly pro-
tective against mHTT, we applied the same strategy to the cells
expressing mutant -synuclein. Consistently, we found that a
reduction in Beclin 1 provided a significant degree of rescue
from mutant -synuclein toxicity (Fig. 8, E and F). Therefore,
our model of autophagosome accumulation–based toxicity
(Fig. 8G) may be relevant to neurodegenerative diseases in
general.
Discussion
In this study, we demonstrate that accumulation of autopha-
gosomes induces cellular toxicity. Our data show that stimula-
tion of autophagosome synthesis can be catastrophic when
autophagy flux is defective. Autophagy is an important source
of energy in times of stress, and a failure in degradation will
eliminate this lifeline (26). When lysosomal activity is limited,
excessive autophagosome synthesis is a futile action to
autophagy and a wasteful process to cells, because this can fur-
ther deplete energy and nutrition, thereby exerting cell toxicity.
It is probable that over an extended time frame, this energy
deficit stress may cause a feedback loop to induce more
autophagosome formation, further exacerbating the problem
and potentially promoting cell death. Because autophagy plays
important roles in various elements of cellular homeostasis,
other feasible contributors to the viability loss could include the
failure to clear toxic substrates or the persistence of faulty and
damaged organelles. Indeed, we observed an increase in ROS
production following accumulation of autophagosomes, sug-
gesting that ROS contributes to the toxicity.
A number of studies have previously demonstrated the path-
ological relevance of disrupting autophagy flux. Perhaps most
notably, combining chemotherapeutic drugs with autophago-
some clearance inhibitors has proven to increase treatment
potency in a variety of tumors (25, 51–54). The rationale behind
these strategies is that tumors often rely very heavily on the
benefits yielded by autophagy: the nutrient supply suits their
high growth demands, and it can help dissipate harmful prod-
ucts of their own microenvironment. Because of this, tumors
often have enhanced basal autophagy rates withmore autopha-
gosome synthesis. Therefore, these malignancies may be more
susceptible to autophagosome accumulation-based toxicity.
Neurodegenerative pathologies such as Alzheimer’s, Parkin-
son’s, and Huntington’s are often associated with aggregation
of toxic proteins. Previous studies, as well as our own data,
indicate that these aggregates induce autophagosome synthesis
while also disrupting autophagic degradation (25, 53, 54). It is
exciting that our data indeed show that reducing accumulation
of autophagosomes ameliorates cell toxicity caused by aggrega-
tion-prone proteins mHTT and -synuclein. It is important to
note that the most promising strategies for manipulating
autophagy in neurodegenerative disease treatment have been
those geared toward restoring flux, rather than solely elevating
autophagosome synthesis (53, 55). Additionally, some previous
reports have also suggested some benefit of depleting
autophagy induction to neurotoxic insults (56, 57). Therefore,
our model of toxicity resulting from accumulation of autopha-
gosomes during periods of lysosome failure is entirely consis-
tent with these studies and provides mechanistic insight into
this phenomenon. The results we present indicate that a reduc-
tion in Beclin 1 is protective for cells with aggregation-prone
proteins by reducing accumulation of autophagosomes. Con-
Figure 7. Lowering accumulation of autophagosomes by partial depletion of autophagosome synthesis alleviates the toxicity ofmutant huntingtin
aggregation. A, SK-N-SH cells were transfected with mRFP-GFP-LC3 and either HA-taggedWT wtHTT or mHTT for 48 h. Cells were then fixed, stained for HA,
and imagedwith confocalmicroscopy. Scale bar, 20m.Thenumbers of autophagosomes (green vesicles) and autolysosomes (red vesiclesminusgreen vesicles)
were calculated (n 30 cells/experiment). Counts are shown asmean S.E. (error bars). ***, p 0.001. B, shown are representative confocal images in A. Note
that autophagosomes co-localizewithmHTT aggregates.C, HeLa cells were transfectedwithGFP-taggedwtHTT ormHTT. After 72 h, cells were harvested (one
set of cells were treated with 25 M CQ for 8 h, as indicated, before harvesting). The cell lysates were subjected to SDS-PAGE and probed with the indicated
antibodies.D, LC3-II levels were quantified over GAPDH. Data are shown as -fold change S.D. (error bars). (n 3).WT, GFP-wtHTT;Mu, GFP-mHTT. *, p 0.05;
***,p0.001. E, SK-N-SH cellswere transfectedwithGFP-HTT exon1with 72Q (HTT-72Q) and either control or Atg16L1 siRNA (10nM) for 48h (topartially knock
downAtg16L1). GFP-positive cells were gated, and cell deathwasmeasured by flow cytometry via propidium iodide staining (n 6 cells/condition). Shown is
the percentage of propidium iodide and GFP–double-positive cells/GFP-positive cells. F, data from E are shown asmean S.D. (error bars). *, p 0.05. Partial
knockdownwas confirmed by immunoblotting. G, SK-N-SH cells were transfected with GFP-HTT-72Q and either control or Beclin 1 siRNA (20 nM) (Bec siRNA-I)
for 48 h (to partially knock downBeclin 1). GFP-positive cellswere gated, and cell deathwasmeasured as in E (n 6 cells/experiment). Shown is the percentage
of propidium iodide and GFP–double-positive cells/GFP-positive cells. H, data are shown as mean  S.D. (error bars). *, p  0.05. Partial knockdown was
confirmedwith immunoblotting. I, SK-N-SH cells were transfected as inG using an alternative Beclin 1 siRNA (Bec siRNA-II). Cell death wasmeasured as before
(n 3 cells/experiment). Data are shown as mean S.D. (error bars). *, p 0.05. Partial knockdown was confirmed with immunoblotting.
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sistent with this, Beclin 1-dependent toxicity has also been
reported during ischemia/reperfusion injury in cardiomyocytes
(58). In addition to Beclin 1, we also targeted another alterna-
tive regulator of autophagy, Atg16L1. Again, Atg16L1 partial
depletion was also protective for cells bearing protein aggre-
gates. Currently, autophagosome synthesis stimulation is often
used to enhance autophagy to alleviate protein aggregation tox-
icity in neurodegeneration.Our study suggests that strategies of
solely stimulating autophagosome synthesis will not be benefi-
cial, but instead deleterious, to neurons in dementia diseases
with protein aggregation.
Our findings suggest that lowering the accumulation of
autophagosomes may have a therapeutic value for neurode-
generative diseases with protein aggregates. Future investi-
gations into the toxicity of autophagosome accumulation in




Rabbit polyclonal antibodies were as follows: anti-mTOR
7C10 (1:500) (CST, 2983); anti-syntaxin-17 (1:1,000) (MBL,
PM076); anti-LC3-II (1:10,000) (Novus Biologicals, NB100-
2220); anti-Atg16L1 (1:1,000) (MBL, PM040Y); anti-Atg10
(1:1,000) (Bio-Rad, AHP1890); anti-Beclin 1 (1:1,000) (Sigma,
B6061; CST, 3738); anti-caspase-3 (1:1,000) (CST, 9662); anti-
cleaved caspase-3 (Asp-175) (1:1,000) (CST, 9661); anti-RIP1
(1:1,000) (CST, 3493); anti-IMPA1 (1:15,000) (Abcam, 184165);
anti-SNAP29 (1:1,000) (Abcam, 138500); and anti-actin
(1:2,000) (Sigma, A2066). Mouse monoclonal antibodies were
as follows: anti-GAPDH (1:5,000) (Ambion, AM4300) and
anti-HA (1:1,000) (Biolegend, 901501). Rap (R0395), CQ
(C6628), Nec (N9037), staurosporine (STS) (S5921), and 3MA
(M9281) were purchased from Sigma. Z-VAD-fmk (catalog no.
627610) was a product of Merck. PI-103 (catalog no. 528100)
was from EMD4 Biosciences. Baf (catalog no. 19–148) was
fromMillipore. Ril was a product of Viva Bioscience (VB2706).
Plasmids
Plasmids mRFP-GFP-LC3 (catalog no. 21074) (28), HA--
synuclein (catalog no. 40824), andGFP--synuclein A53T (cat-
alog no. 40823) (59) were obtained from Addgene. HA-tagged
HTT-72Q (60), GFP-HTT-21Q, and GFP-HTT-72Q (61) were
described previously. To obtain mCherry-HTT-72Q and
mCherry- synuclein, mCherry cDNA was cloned into
pcDNA3 flanked with HindIII/BamHI sites. To ligate HTT-
72Q into pcDNA mCherry, HTT-72Q was cut with BglII/
EcoRI, and pcDNA mCherry was cut with BamHI/EcoRI. To
ligate -synuclein A53T into pcDNA mCherry, -synuclein
was cut with BamHI/XhoI, and pcDNA3mCherry was cut with
BglII/SalI. Plasmids were confirmed by DNA sequencing.
Scramble shRNA (Addgene, 1864) and mTOR shRNA (Add-
gene, 1855) was a gift from Dr. David Sabatini (62). STX-17
shRNA was purchased from Sigma (TRCN0000379933).
Cell culture
HeLa, HEK293, SK-N-SH, RT4-D6P2T (from Sigma,
93011415), and LAMP1/2 double knock-out orwild-typeMEFs
(gifts from Dr. P. Saftig, Kiel, Germany) were cultured in
DMEM (D6046) medium with 10% FBS (12133C) (Sigma).
mRFP-GFP-LC3–stably expressing HeLa cells, described pre-
viously (28, 60), were cultured inDMEMwith 10% FBS.Human
primary schwannomas were cultured as described previously
(63) with full ethical approval.
Plasmids were transfected into cells either alone or with
siRNA using Lipofectamine 2000 (Thermo Scientific), accord-
ing to the manufacturer’s instructions, for the length of time
indicated in each figure legend.
siRNA transfection
Cells were split to confluence of 60–80% and incubated in
antibiotic-free DMEM (containing 10% FBS). siRNAs were
transfected at a final concentration of 50 nM (unless otherwise
stated), using Lipofectamine 2000 as per the manufacturer’s
instructions (Invitrogen). Medium was exchanged 24 h post-
transfection, with cells typically incubated for a further 24–48
h before harvesting/analyzing. Human RIP1 siRNA (J-004445-
07) was obtained from Dharmacon. All other siRNAs were
purchased from the suppliers as indicated. Human siRNA
sequences were as follows: mTOR (Invitrogen), 5-GGGCAU-
GAAUCGGGAUGAU-3 (sense); syntaxin-17 (STX-17) (Invit-
rogen), 5-GACUGUUGGUGGAGCAUUU-3 (sense); Vps33A
(Invitrogen), 5-GCAAGGCAAUAGUUUGGGA-3 (sense);
Atg10 (Invitrogen), 5-CCAUGGGACACUAUUACGC-3
(sense); Atg16L1 (Dharmacon, Smartpool); Beclin 1 siRNA-1
(Dharmacon), 5-GGUCUAAGACGUCCAACAA-3 (sense);
Beclin 1 siRNA-2 (CST), 5-GGUCUAAGACGUCCAA-
CAA-3 (sense); caspase-3 (CST), 5-UGGAUUAUCCU-
GAGAUGGG-3 (sense); control siRNA-1 (Dharmacon), 5-
CGUACGCGGAAUACUUCGA-3 (sense); IMPA1 (Ambion),
5-GGUCAAAAAUUUGGAACUU-3 (sense); SNAP29 (Amb-
ion), 5-CCCACACCUUCGAGCCUAU-3 (sense).
Figure 8. Lowering accumulation of autophagosomes by partial depletion of autophagosome synthesis alleviates -synuclein toxicity. A, SK-N-SH
cells were transfected with mRFP-GFP-LC3 and either control (Ctrl) or synuclein (Syn) for 48 h. Cells were fixed, stained for HA, and imaged with confocal
microscopy. Scale bars, 20 m. B, the numbers of autophagosomes (green vesicles) and autolysosomes (red vesiclesminus green vesicles) were calculated (n
20 cells/experiment). Counts are shown asmean S.D. (error bars). ***, p 0.001. C, HeLa cells were transfectedwith GFP or GFP–-synuclein. After 72 h, cells
were harvested (one set of cells were treated with 25 M CQ for 8 h before harvesting). The cell lysates were subjected to SDS-PAGE and probed with the
indicated antibodies. D, the ratios of LC3-II/GAPDHwere quantified. Data are shown as -fold change S.D. (n 3). *, p 0.05; ***, p 0.001. E, SK-N-SH cells
were transfected with GFP-Syn-A53T and either control or Beclin 1 siRNA (20 nM) for 48 h. GFP-positive cells were gated, and cell death wasmeasured by flow
cytometry via propidium iodide staining (n 6 cells/condition). Shown is the percentage of propidium iodide and GFP–double-positive cells/GFP-positive
cells. F, data from E are shown as mean  S.D. *, p  0.05. G, proposed model of autophagosome accumulation-based toxicity. During periods of stress,
autophagosome synthesis will be promoted. However, if autophagosome–lysosome fusion is rendered dysfunctional, further non-fused autophagosome
synthesis is futile to the cell because autophagy cannot be completed. Therefore, the synthesis of non-fused autophagosomes is detrimental to cell survival by
causing more strain on energy levels as well as a failure to clear potentially harmful toxins.
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Immunocytochemistry
Cells were washed with PBS twice and fixed with 4% parafor-
maldehyde for 10 min. Following three further PBS washes,
cells were permeabilized with 0.5% Triton in PBS for 10 min.
Cells were blocked in blocking buffer (1% BSA, 1% heat inacti-
vated goat serum in PBS) for 30 min at room temperature and
incubated with primary antibodies overnight at 4 °C. Cells were
again washed with three 10-min PBS washes, incubated with
secondary antibodies for 30 min, and then followed by an addi-
tional three 10-min PBS washes. Slides were mounted with
DAPI (3 g/ml).
mRFP-GFP-LC3 assay
HeLa cells stably expressing mRFP-GFP-LC3 were treated
with compounds or siRNAs at the indicated concentrations.
After 24 h, cells were fixed in 2% paraformaldehyde for 5 min.
Cellomics (Arrayscan VTI) was used to score green and red
vesicles. Green vesicles are considered to be autophagosomes,
and red vesicles are considered to be both autophagosomes and
autolysosomes. The number of autolysosomes was obtained by
subtracting the number of green vesicles from that of the red
vesicles.
Cell proliferation assay
Cell proliferation was measured with the BrdU cell prolifer-
ation assay kit (CST, 6813) following the manufacturer’s
instructions. Absorbance was read at 450 nm with the TECAN
GENios V4.62-07/01 microplate reader (Tecan, Reading, UK)
and XFLUOR4 version V 4.51 software (Tecan).
Cell viability assay
MTTwas purchased from Invitrogen (M6494). Briefly, 10 l
of a 12 mM MTT stock solution was added to culture medium
and incubated at 37 °C for 4 h.Mediumwas exchangedwith 100
l of DMSO, mixed by pipetting, and placed on a plate shaker
for 10 min. Absorbance was read at 562 nm and a reference
measurement was taken at 650 nm using the TECAN GENios
V4.62-07/01 microplate reader and XFLUOR4 version V 4.51
software. For each assay, the control was set as 100% viability,
with all other treatments corrected against this value.
Cytotoxicity assay
Cell cytotoxicity was measured by the CytoTox 96 non-
radioactive cytotoxicity assay following the manufacturer’s
instructions (Promega, G1780). For this assay, all cells were
cultured in 96-well plates with medium-only controls. Briefly,
following the desired treatment incubation, a 50-l volumewas
taken from each well and transferred to a fresh 96-well plate.
From here, 50l of CytoTox 96 reagent was added to each well,
and plates were incubated for 30 min at room temperature
shielded from light. After incubation, 50l of stop solution was
added, and absorbance was read at 490 nm using the Tecan
GENios V4.62–07/01 microplate reader and XFLUOR4 ver-
sion V 4.51 software.
Flow cytometry
Cell death assay—Trypsinized cells were washed twice with
cold PBS and resuspended in 1 binding buffer (10mMHEPES,
pH 7.4, 140mMNaCl, 2.5 mMCaCl2) at 1 106 cells/ml. 100l
of these cells were transferred to a FACS tube, treated with 5l
of propidium iodide (30 g/ml) (Sigma 81845), and incubated
for 15min at room temperature. Each tube had a further 200l
of 1 binding buffer added and then was analyzed by flow
cytometry.
DHE staining—Cells were incubated with medium contain-
ing 10 M dihydroethidium (Sigma, D7008) for 20 min at 37 °C
and then washed twice with PBS. Next cells were trypsinized,
washed with flow fluid (PBS with 2% FBS), and then resus-
pended in 500 l of flow fluid. Flow cytometry was performed
using the BD Biosciences Accuri C6 flow cytometer with data
analyzed with the accompanying software.
ATP assay
Intracellular ATP levels were measured with the Cell Titer-
Glo luminescent cell viability assay kit (Promega, G7571)
according to the manufacturer’s instruction. Briefly, 100 l of
Cell Titer-Glo reagent was added to the culture medium. Cells
were placed on a shaker for 5 min and then incubated at room
temperature for 10 min. The SPECTRA Max M5 reader was
used for luminescent reading.
LysoSensor staining
Cells were stained with 1 M LysoSensor Green DND-189
(Thermo Fisher, L7535) for 30 min at 37 °C. Culture medium
was then replaced, and live imaging was performed via confocal
microscopy at an excitation wavelength of 488 nm.
Quantitative RT-PCR analysis
RNAwas isolated with TRIzol reagent as instructed (Invitro-
gen). For qPCR analysis, 1 g of RNA was reverse transcribed
(Applied Biosystems, Paisley, UK) using cycles of 25 °C (10
min), 37 °C (120min), and 85 °C (5min). cDNA templates were
then used for qPCR using the LightCycler 480 DNA SYBR
Green I Master kit (Roche Applied Science) in a LightCycler
480 II system (Roche Applied Science). All primers were from
Sigma and were used at 0.5 M. Actin was used as a control to
normalize the data. Actin primers were 5-ACTGGCATCGT-
GATGGACTC-3 (forward) and 5-TCAGGCAGCTCG-
TAGCTCTT-3 (reverse). mTOR primers were 5-TAA-
GAAAACGGGGACCACAG-3 (forward) and 5-TGA-
GAGAAGTCCCGACCAGT-3 (reverse). Vps33A primers
were 5-CCCACAGGACTGCAGAAGA-3 (forward) and 5-
TCCAACTGGGAGAGAAATCG-3 (reverse).
Electronmicroscopy
Cells were fixed in 2.5% glutaraldehyde diluted in 0.1 M
sodiumcacodylate buffer for 2 h at room temperature. The cells
were then rinsed in 0.1 M sodium cacodylate buffer, post-fixed
in 1% osmium tetroxide diluted in the same buffer, rinsed with
0.1 M sodium cacodylate, and then dehydrated in an ascending
ethanol series. After dehydration, the cells were embedded in
agar low viscosity resin and polymerized overnight at 60 °C.
Ultra-thin sections (90 nm) were cut using a Lecia EM UC7
ultramicrotome and post-stained with uranyl acetate and lead
citrate. Sample sections were viewed on a JEOL 1400 transmis-
sion electron microscope (Jeol, Welwyn Garden City, UK) at
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120 kV, using a variety of magnifications. For autophagosome
quantification, 25 micrographs were taken with a systematic
random sampling from each sample.
Statistics
A t test was used, and p values were determined by uncondi-
tional logistical regression analysis by using the general log
linear option of SPSS version 9.1 (***, p 0.001; **, p 0.01; *,
p  0.05; NS, not significant). Data from three independent
experiments were analyzed (unless otherwise stated).
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